标签归档：hexasodium

myo-Inositol trispyrophosphate hexasodium(Synonyms: ITPP hexasodium)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

myo-Inositol trispyrophosphate hexasodium (Synonyms: ITPP hexasodium)

myo-Inositol trispyrophosphate (ITPP) hexasodium 是血红蛋白 (haemoglobin) 调节剂，是一种变构效应物，可降低血红蛋白的氧结合亲和力并促进红细胞释放氧。myo-Inositol trispyrophosphatehexasodium 可以逆转缺氧，控制肿瘤生长并改善化疗反应。

myo-Inositol trispyrophosphate hexasodium(Synonyms: ITPP hexasodium)

myo-Inositol trispyrophosphate hexasodium Chemical Structure

CAS No. : 23103-35-7

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

myo-Inositol trispyrophosphate (ITPP) hexasodium, a modifier of haemoglobin, is an allosteric effector that reduces the oxygen‐binding affinity of haemoglobin and facilitates the release of oxygen by red blood cells. myo-Inositol trispyrophosphate can reverse hypoxia, control tumor growth and improve chemotherapy response[1][2][3].

体外研究
(In Vitro)

myo-Inositol trispyrophosphate hexasodium (10 mmol/L; 2 hours) significantly inhibits OCR in all six cell lines (FSaII, SiHa, MDA‐MB‐231, NT2, 9L‐glioma and rhabdomyosarcoma) [2].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究
(In Vivo)

myo-Inositol trispyrophosphate hexasodium (2 g/kg weekly; IP; 7weeks) sustains its significant effect on life prolongation[1].
myo-Inositol trispyrophosphate hexasodium (1.5 g/kg weekly; IV; for 8 weeks) remains metastasis-free on pancreatic carcinomas in immunocompetent male Lewis rats weighing 120-150 g with DSL-6A/C1 cells. myo-Inositol trispyrophosphate hexasodium restores the pO2 pressure in tumors reducing hypoxia-inducible and proangiogenic factors[1].
myo-Inositol trispyrophosphate hexasodium (2 g/kg; once daily for 2 days) shows the most elevated tumour oxygenation at 2 hours in four mouse tumour models (mouse fibrosarcoma FSaII implanted in C3H mice, mouse mammary tumour NT2 in FVb/Nrj mice, human breast cancer MDA‐MB‐231 in NMRI nude mice and human cervix squamous cell carcinoma SiHa in NMRI nude mice) and two rat tumour models (rat 9L‐glioma in Fischer F344 rats and rat rhabdomyosarcoma in WAG/Rij rats)[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Nude mice (20 g) with MiaPaCa-2 or DSL-6A/C1 cells[1]
Dosage: 2 g/kg (weekly)
Administration: IP; weekly; 7weeks
Result: Sustained its significant effect on life prolongation.

分子量

737.88

Formula

C6H6Na6O21P6
CAS 号

23103-35-7
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Zahary Raykov, et al. Myo-inositol trispyrophosphate-mediated hypoxia reversion controls pancreatic cancer in rodents and enhances gemcitabine efficacy. Int J Cancer. 2014 Jun 1;134(11):2572-82.

    [2]. Ly-Binh-An Tran, et al. Impact of myo-inositol trispyrophosphate (ITPP) on tumour oxygenation and response to irradiation in rodent tumour models. J Cell Mol Med. 2019 Mar;23(3):1908-1916.

    [3]. Marta Oknińska, et al. Treatment of hypoxia-dependent cardiovascular diseases by myo-inositol trispyrophosphate (ITPP)-enhancement of oxygen delivery by red blood cells. J Cell Mol Med. 2020 Feb;24(3):2272-2283.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

myo-Inositol trispyrophosphate hexasodium(Synonyms: ITPP hexasodium)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

myo-Inositol trispyrophosphate hexasodium (Synonyms: ITPP hexasodium)

myo-Inositol trispyrophosphate (ITPP) hexasodium 是血红蛋白 (haemoglobin) 调节剂，是一种变构效应物，可降低血红蛋白的氧结合亲和力并促进红细胞释放氧。myo-Inositol trispyrophosphatehexasodium 可以逆转缺氧，控制肿瘤生长并改善化疗反应。

myo-Inositol trispyrophosphate hexasodium(Synonyms: ITPP hexasodium)

myo-Inositol trispyrophosphate hexasodium Chemical Structure

CAS No. : 23103-35-7

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

myo-Inositol trispyrophosphate (ITPP) hexasodium, a modifier of haemoglobin, is an allosteric effector that reduces the oxygen‐binding affinity of haemoglobin and facilitates the release of oxygen by red blood cells. myo-Inositol trispyrophosphate can reverse hypoxia, control tumor growth and improve chemotherapy response[1][2][3].

体外研究
(In Vitro)

myo-Inositol trispyrophosphate hexasodium (10 mmol/L; 2 hours) significantly inhibits OCR in all six cell lines (FSaII, SiHa, MDA‐MB‐231, NT2, 9L‐glioma and rhabdomyosarcoma) [2].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究
(In Vivo)

myo-Inositol trispyrophosphate hexasodium (2 g/kg weekly; IP; 7weeks) sustains its significant effect on life prolongation[1].
myo-Inositol trispyrophosphate hexasodium (1.5 g/kg weekly; IV; for 8 weeks) remains metastasis-free on pancreatic carcinomas in immunocompetent male Lewis rats weighing 120-150 g with DSL-6A/C1 cells. myo-Inositol trispyrophosphate hexasodium restores the pO2 pressure in tumors reducing hypoxia-inducible and proangiogenic factors[1].
myo-Inositol trispyrophosphate hexasodium (2 g/kg; once daily for 2 days) shows the most elevated tumour oxygenation at 2 hours in four mouse tumour models (mouse fibrosarcoma FSaII implanted in C3H mice, mouse mammary tumour NT2 in FVb/Nrj mice, human breast cancer MDA‐MB‐231 in NMRI nude mice and human cervix squamous cell carcinoma SiHa in NMRI nude mice) and two rat tumour models (rat 9L‐glioma in Fischer F344 rats and rat rhabdomyosarcoma in WAG/Rij rats)[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Nude mice (20 g) with MiaPaCa-2 or DSL-6A/C1 cells[1]
Dosage: 2 g/kg (weekly)
Administration: IP; weekly; 7weeks
Result: Sustained its significant effect on life prolongation.

分子量

737.88

Formula

C6H6Na6O21P6
CAS 号

23103-35-7
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Zahary Raykov, et al. Myo-inositol trispyrophosphate-mediated hypoxia reversion controls pancreatic cancer in rodents and enhances gemcitabine efficacy. Int J Cancer. 2014 Jun 1;134(11):2572-82.

    [2]. Ly-Binh-An Tran, et al. Impact of myo-inositol trispyrophosphate (ITPP) on tumour oxygenation and response to irradiation in rodent tumour models. J Cell Mol Med. 2019 Mar;23(3):1908-1916.

    [3]. Marta Oknińska, et al. Treatment of hypoxia-dependent cardiovascular diseases by myo-inositol trispyrophosphate (ITPP)-enhancement of oxygen delivery by red blood cells. J Cell Mol Med. 2020 Feb;24(3):2272-2283.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务